| Literature DB >> 31089366 |
Mohammad Zavarshani1, Malahat Ahmadi1, Habib Dastmalchi Saei1, Ali Asghar Tehrani2, Bahram Dalir Naghadeh3.
Abstract
Pseudomonas aeruginosa is one of the most common causes ofEntities:
Keywords: Ciprofloxacin; Keratitis; Pseudomonas; Rabbit; Silver
Year: 2019 PMID: 31089366 PMCID: PMC6487424
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
MIC and MBC of Ciprofloxacin (µg mL-1) Ag-NPs (mg L-1) and their combination
|
|
|
|
|---|---|---|
| Ciprofloxacin | 5.85 | 11.71 |
| Silver nanoparticles | 15.62 | 31.25 |
| Ciprofloxacin + Silver nanoparticles | 0.73 | 1.46 |
| 0.97 | 1.95 |
Figure 1Dense opacity (A) blepharospasm and ocular discharge (B) 12 and 48 h after bacterial inoculation, respectively
Figure 2Different scoring of corneal opacity in groups CO + (A), C+N+B at 108 h (B) and 204 h (C)
The details of Kruskal-Wallis test of corneal opacity scores (Mean rank) among all treatment groups
|
|
| |
|---|---|---|
| Chi-Square | 25.422 | 26.647 |
| df | 7 | 7 |
| Asymp. Sig. | 0.001 | 0.000 |
P value < 0.05
Comparison of corneal opacity scores (Mean rank) between two groups
|
|
|
|
|---|---|---|
|
| 28.00c | 28.00b |
| N | 26.00c | 26.00b |
| N+B | 22.00c | 24.00b |
| C+N+B | 10.50b | 7.50c |
| C+B | 13.38bc | 13.63c |
| C | 16.25bc | 15.75c |
| C+N | 13.38bc | 13.63c |
| CO − | 2.50a | 3.50a |
Insignificant differences (P > 0.05) between different treatments are shown by different letters (a, b, c and d) in each group.
The details of ANOVA test of number of days of blepharospasm and ocular discharge (Mean ± SD) among all treatment groups
|
|
|
|
|
|
|---|---|---|---|---|
| Sum of Squares | 54.969 | 54.875 | 191.5000 | 168.000 |
| df | 7 | 7 | 7 | 7 |
| F | 251.286 | 188.43 | 82.071 | 57.600 |
| Sig. | 0.000 | 0.000 | 0.000 | 0.000 |
P value < 0.05
Comparison of number of days of blepharospasm and ocular discharge (Mean ± SD) between two groups
|
|
|
|
|
|
|---|---|---|---|---|
| CO + | 4.00 ± 0.00c | 4.00 ± 0.00c | 8.00 ± 0.00f | 8.00 ± 0.00e |
| N | 4.00 ± 0.00c | 4.00 ± 0.00c | 7.25 ± 0.50ef | 7.25 ± 0.50de |
| N+B | 4.00 ± 0.00c | 4.00 ± 0.00c | 7.00 ± 0.00def | 7.00 ± 0.00cde |
| C+N+B | 3.25 ± 0.50b | 3.50 ± 0.57b | 3.25 ± 0.50b | 4.00 ± 0.81b |
| C+B | 4.00 ± 0.00c | 4.00 ± 0.00c | 5.75 ± 1.25cd | 5.50 ± 1.29bcd |
| C | 4.00 ± 0.00c | 4.00 ± 0.00c | 6.50 ± 0.57cde | 6.25 ± 0.50cd |
| C+N | 4.00 ± 0.00c | 4.00 ± 0.00c | 5.25 ± 0.50c | 5.75 ± 0.50cd |
| CO − | 0.00 ± 0.00a | 0.00 ± 0.00a | 0.00 ± 0.00a | 0.25 ± 0.50a |
Insignificant differences (P > 0.05) between different treatments are shown by different letters (a, b, c, d, e and f) in each group.
The details of ANOVA test of bacterial counts (log CFU mL-1) (Mean ± SD) among all treatment groups
|
|
| |
|---|---|---|
| Sum of Squares | 341.469 | 634.969 |
| df | 7 | 7 |
| F | 67.870 | 129.972 |
| Sig. | 0.000 | 0.000 |
P value < 0.05
Comparison of bacterial counts (log CFU mL-1).(Mean ± SD) between two groups
|
|
|
|
|---|---|---|
| CO + | 11.25 ± 0.92d | 15.00 ± 0.81d |
| N | 6.50 ± 1.29c | 6.50 ± 1.29c |
| N+B | 7.50 ± 1.29c | 6.50 ± 1.29c |
| C+N+B | 2.50 ± 0.57ab | 1.50 ± 0.57ab |
| C+B | 3.50 ± 0.57b | 2.50 ± 0.57b |
| C | 3.50 ± 0.57b | 2.50 ± 0.57b |
| C+N | 2.75 ± 0.50b | 1.75 ± 0.50ab |
| CO − | 0.75 ± 0.50a | 0.50 ± 0.57a |
Insignificant differences (P > 0.05) between different treatments are shown by different letters (a, b, c and d) in each group.